Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. 

CEO
Paul Hudson
CEOPaul Hudson
Employees
84,587
Employees84,587
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
84,587
Employees84,587

SNY Key Statistics

Market cap
114.69B
Market cap114.69B
Price-Earnings ratio
11.69
Price-Earnings ratio11.69
Dividend yield
3.40%
Dividend yield3.40%
Average volume
3.65M
Average volume3.65M
High today
$47.68
High today$47.68
Low today
$47.02
Low today$47.02
Open price
$47.38
Open price$47.38
Volume
2.72M
Volume2.72M
52 Week high
$60.12
52 Week high$60.12
52 Week low
$44.73
52 Week low$44.73

SNY News

Seeking Alpha 3d
Sanofi’s Tzield approved in China to delay type 1 diabetes progression

Sanofi (NASDAQ:SNY) said on Wednesday that Tzield was approved in China as the first disease-modifying therapy for adult and pediatric patients with stage 2 typ...

Sanofi’s Tzield approved in China to delay type 1 diabetes progression
TipRanks 5d
Sanofi upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Sanofi (SNY) to Overweight from Equal Weight with a price target of $58, up from $56. The firm believes the recent pullback in the share...

TipRanks 6d
Sanofi’s Promising Ulcerative Colitis Study: What Investors Need to Know

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

Analyst ratings

72%

of 25 ratings
Buy
72%
Hold
28%
Sell
0%

More SNY News

TipRanks 6d
Sanofi’s Latest Clinical Study: A New Hope for Advanced Solid Tumors

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

TipRanks 6d
Sanofi’s Promising Phase 2a/b Study on Amlitelimab for Celiac Disease

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

TipRanks 6d
Sanofi’s Promising New Study on Rilzabrutinib for ITP: A Potential Game-Changer

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock pow...

TipRanks 6d
Sanofi’s Nirsevimab Study: A Promising Step in RSV Prevention

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock pow...

TipRanks 6d
Sanofi’s New Vaccine Study: A Potential Game-Changer in Meningococcal Prevention

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

TipRanks 6d
Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock pow...

TipRanks 6d
Sanofi’s Promising Phase 2a Study on Kidney Disease Treatments: An Investor’s Insight

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.